Cytokine levels in malignant ascites and peripheral blood of patients with advanced ovarian cancer

被引：35
|
作者：
Radke, J
Schmidt, D
Bohme, M
Schmidt, U
Weise, W
Morenz, J
机构：
[1] OTTO VONGUERICKE UNIV,FAK MED,INST IMMUNOL,D-39008 MAGDEBURG,GERMANY
[2] OTTO VONGUERICKE UNIV,FAK MED,KLIN ST MARIENSTIFT MAGDEBURG,D-39008 MAGDEBURG,GERMANY
[3] OTTO VONGUERICKE UNIV,FAK MED,INST BIOMETRIE & MED INFORMAT,D-39008 MAGDEBURG,GERMANY
来源：
GEBURTSHILFE UND FRAUENHEILKUNDE | 1996年 / 56卷 / 02期
关键词：
D O I：
10.1055/s-2007-1022247
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
The concentrations of various cytokines were examined by ELISA in blood and in ascites from 14 patients with advanced ovarian cancer (stage IV). The control group consisted of 6 patients with benign gynaecological disorders. Compared with patients with benign gynaecological disorders, ascites and/or plasma of patients with ovarian cancer showed significantly higher levels of IL-6, IL-8, IL-10, TNF-alpha, and sIL-2R. There were no increases of IL-1 alpha, IL-1 beta, IL-2, IFN-gamma, and sCD14 levels. The possible pathogenetic significance of cytokines in ovarian cancer is discussed.
引用
收藏
页码：83 / 87
页数：5
相关论文
共 50 条
  • [1] LEUKOCYTES AND LYMPHOCYTE SUBSETS IN PERIPHERAL-BLOOD AND MALIGNANT ASCITES OF PATIENTS WITH OVARIAN-CANCER
    RADKE, J
    SCHMIDT, D
    BOHME, M
    MORENZ, J
    WEISE, W
    GEBURTSHILFE UND FRAUENHEILKUNDE, 1994, 54 (12) : 675 - 678
  • [2] Aflibercept for malignant Ascites Targeted Therapy in advanced Ovarian Cancer
    Knoedler, M.
    ONKOLOGE, 2013, 19 (01): : 62 - 63
  • [3] A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites
    Colombo, Nicoletta
    Mangili, Giorgia
    Mammoliti, Serafina
    Kalling, Marten
    Tholander, Bengt
    Sternas, Lars
    Buzenet, Giliane
    Chamberlain, Donald
    GYNECOLOGIC ONCOLOGY, 2012, 125 (01) : 42 - 47
  • [4] ASCITES LEVELS OF HAPTOGLOBIN IN PATIENTS WITH OVARIAN-CANCER
    ELG, SA
    CARSON, LF
    FOWLER, JM
    TWIGGS, LB
    MORADI, MM
    RAMAKRISHNAN, S
    CANCER, 1993, 71 (12) : 3938 - 3941
  • [5] Doxorubicin levels in the serum and ascites of patients with ovarian cancer
    Gotlieb, W. H.
    Bruchim, I.
    Ben-Baruch, G.
    Davidson, B.
    Zeltser, A.
    Andersen, A.
    Olsen, H.
    EJSO, 2007, 33 (02): : 213 - 215
  • [6] Ovarian cancer-associated ascites associated with elevated cytokine and chemokine levels
    Giuntoli, R. L.
    Rogers, O.
    Webb, T. J.
    Bristow, R. E.
    Diaz, T.
    Oelke, M.
    GYNECOLOGIC ONCOLOGY, 2009, 112 (02) : S144 - S145
  • [7] Transforming growth factor-alpha levels in the serum and ascites of patients with advanced epithelial ovarian cancer
    Saltzman, AK
    Hartenbach, EM
    Carter, JR
    Contreras, DN
    Twiggs, LB
    Carson, LF
    Ramakrishnan, S
    GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 1999, 47 (03) : 200 - 204
  • [8] Emerging treatment options for management of malignant ascites in patients with ovarian cancer
    Eskander, Ramez N.
    Tewari, Krishnansu S.
    INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2012, 4 : 395 - 404
  • [9] RECURENT MALIGNANT ASCITES IN PATIENTS WITH ADVANCED OVARIAN CANCER: A REVIEW OF THERAPEUTIC APPROACHES ACCENTING ASSESSMENT OF QUALITY OF LIFE
    Nalezinska, M.
    Chovanec, J.
    Slama, O.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 1546 - 1546
  • [10] Characteristics of Selected Adipokines in Ascites and Blood of Ovarian Cancer Patients
    Wroblewski, Marcin
    Szewczyk-Golec, Karolina
    Holynska-Iwan, Iga
    Wroblewska, Joanna
    Wozniak, Alina
    CANCERS, 2021, 13 (18)
12345